Clinical phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in patients with AML or MDS considered ineligible to standard conditioning regimens.

Trial Profile

Clinical phase III trial to compare Treosulfan-based conditioning therapy with Busulfan-based reduced-intensity conditioning (RIC) prior to allogeneic haematopoietic stem cell transplantation in patients with AML or MDS considered ineligible to standard conditioning regimens.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs Treosulfan (Primary) ; Busulfan
  • Indications Acute myeloid leukaemia; Graft-versus-host disease; Myelodysplastic syndromes
  • Focus Registrational; Therapeutic Use
  • Sponsors Medac
  • Most Recent Events

    • 20 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 27 Aug 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
    • 09 Mar 2013 Planned number of patients changed from 545 to 960 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top